Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Gegen Qinlian Decoction for Diarrhea-predominant Irritable Bowel Syndrome
NCT04312477Phase 1Unknown
- Sponsor
- Xiyuan Hospital
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of modified Gegen Qinlian decoction in Irritable bowel syndrome with diarrhea (IBS-D) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: IBS Symptom Severity Scale at 4 weeks and Clinical Global Impression of Severity Scale at 4 weeks. Status: unknown.
02
Drugs
modified Gegen Qinlian decoction
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT04312477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312477.